121507-66-2

Basic information

• Product Name: phenyl 4-oxo-3,4-dihydro-1(2H)-pyridinecarboxylate
• Synonyms: phenyl 4-oxo-3,4-dihydro-1(2H)-pyridinecarboxylate
• CAS NO: 121507-66-2
• Molecular Formula: C₁₂H₁₁NO₃
• Molecular Weight: 217.22064
• Mol File: 121507-66-2.mol
• Article Data: 5

Chemical Properties

• Appearance: /
• CAS DataBase Reference: phenyl 4-oxo-3,4-dihydro-1(2H)-pyridinecarboxylate(CAS DataBase Reference)
• NIST Chemistry Reference: phenyl 4-oxo-3,4-dihydro-1(2H)-pyridinecarboxylate(121507-66-2)
• EPA Substance Registry System: phenyl 4-oxo-3,4-dihydro-1(2H)-pyridinecarboxylate(121507-66-2)

Safety Data

• Hazardous Substances Data: 121507-66-2(Hazardous Substances Data)

Upstream product

• 620-08-6 4-methoxypyridine 
• 1885-14-9 phenyl chloroformate 
• 24681-60-5 1,2,3,4-tetrahydro-4-oxopyridine 

Downstream Products

• 121507-67-3 4-hydroxy-1-phenoxycarbonyl-1,2,3,4-tetrahydropyridine 
• 121507-69-5 2-methyl-1-phenoxycarbonyl-1,2,5,6-tetrahydropyridine 
• 121507-68-4 4-methoxy-1-phenoxycarbonyl-1,2,3,4-tetrahydropyridine 
• 121507-70-8 2-n-butyl-1-phenoxycarbonyl-1,2,5,6-tetrahydropyridine 
• 121507-71-9 2-(4-chlorobutyl)-1-phenoxycarbonyl-1,2,5,6-tetrahydropyridine 
• 121507-72-0 2-(2-ethoxycarbonylethyl)-1-phenoxycarbonyl-1,2,5,6-tetrahydropyridine 
• 121507-73-1 2-(3-ethoxycarbonylpropyl)-1-phenoxycarbonyl-1,2,5,6-tetrahydropyridine 
• 1609582-79-7 phenyl 5-(2-ethoxy-1,1-difluoro-2-oxoethyl)-4-oxo-2,3-dihydropyridine-1-carboxylate 
• 325486-45-1 tert-butyl 4-oxo-3,4-dihydropyridine-1(2H)-carboxylate 

Relevant articles and documents

Catalytic enantioselective conjugate addition of dialkylzinc reagents to N-substituted-2,3-dehydro-4-piperidones

The first, highly enantioselective, copper/phosphoramidite-catalyzed conjugate addition of dialkylzinc reagents to N-substituted 2,3-dehydro-4- piperidones is described. The Royal Society of Chemistry 2005.

Design, Synthesis, and Pharmacological Characterization of a Neutral, Non-Prodrug Thrombin Inhibitor with Good Oral Pharmacokinetics

Despite extensive research on small molecule thrombin inhibitors for oral application in the past decades, only a single double prodrug with very modest oral bioavailability has reached human therapy as a marketed drug. We have undertaken major efforts to identify neutral, non-prodrug inhibitors. Using a holistic analysis of all available internal data, we were able to build computational models and apply these for the selection of a lead series with the highest possibility of achieving oral bioavailability. In our design, we relied on protein structure knowledge to address potency and identified a small window of favorable physicochemical properties to balance absorption and metabolic stability. Protein structure information on the pregnane X receptor helped in overcoming a persistent cytochrome P450 3A4 induction problem. The selected compound series was optimized to a highly potent, neutral, non-prodrug thrombin inhibitor by designing, synthesizing, and testing derivatives. The resulting optimized compound, BAY1217224, has reached first clinical trials, which have confirmed the desired pharmacokinetic properties.

THE ADDITION OF ALKYLZINC IODIDES TO 1-(PHENOXYCARBONYL)-2,3-DIHYDROPYRIDINIUM SALTS. A SYNTHESIS OF 2-ALKYL-Δ3-PIPERIDINES.

Several 2-alkyl-1-(phenoxycarbonyl)-Δ3-piperidines were prepared by the addition of alkylzinc iodides to 1-(phenoxycarbonyl)-2,3-dihydropyridinium salts.